Dublin-based medical technology company Medtronic plc this week announced a new outcomes-based agreement with Aetna for type 1 and type 2 diabetes patients currently on multiple daily insulin injections for diabetes management.
The agreement will measure health outcomes for patients that choose to transition to pump therapy using a Medtronic insulin pump featuring SmartGuard technology, including the new MiniMed 670G system, which constantly self-adjusts to keep patients’ blood sugar levels in range based on their personalized needs, according to Medtronic.
The outcomes-based agreement continues to provide Aetna members access to Medtronic’s advanced diabetes technologies and comprehensive support services, including the new MiniMed 670G system.
The agreement ties a component of Medtronic’s reimbursement to successfully meeting agreed-upon clinical improvement thresholds for Aetna members with type 1 and type 2 diabetes.
